Her Child’s Cancer Showed Her the Importance of What Clinicians Do
نویسندگان
چکیده
منابع مشابه
What Made Her Give Up Her Breasts: a Qualitative Study on Decisional Considerations for Contralateral Prophylactic
Women who carry a mutation of BRCA1 or BRCA 2 gene have an increased lifetime risk of breast cancer as high as 50-85% (Matloff et al., 2000; Antoniou et al., 2003; King et al., 2003). The annual risk for contralateral cancer for mutated BRCA1 or BRCA2 carrier is increased by approximately 3% and the overall risk may be as high as 52% by age 70 years. Options for carriers include early and regul...
متن کاملExpression of heregulin, phosphorylated HER-2, HER-3 and HER-4 in HER-2 negative breast cancers.
A significant number of HER-2 amplified breast cancers is effectively treated by trastuzumab and further shows receptor-enhanced chemosensitivity. Recent studies have postulated transactivation of HER-2 also in tumors expressing phosphorylated/activated HER-2 (pHER-2) and of the HER-3/HER-4 ligand heregulin (HRG), independent of HER-2 amplification. As a consequence, a subset of tumors without ...
متن کاملCD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients.
PURPOSE CD4(+)CD25(bright) regulatory T cells (Tregs) are increased in patients with several malignancies and correlate with disease stage and prognosis. Breast cancer patients represent a heterogeneous population with unpredictable disease progression even at advanced stages. Circulating Tregs in correlation with HER-2/neu (HER) status and treatment with chemotherapy, either alone or in combin...
متن کاملAnti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies.
Two members of the EGF receptor family, HER2 and HER3, act as key oncogenes in breast cancer cells. A MAb against HER2, trastuzumab, interferes with HER2 signaling and istherapeutically effective in humans. Here, we explored the biologic effects of an antibody against HER3 (alpha-HER3ECD) in the invasive breast cancer cell lines MCF-7ADR and MDA-MB-468. Pretreating the breast cancer cells with ...
متن کاملHER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
OBJECTIVE In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value. PATIENTS AND METHODS Overall 208 patients with CRLM were enrolled. HER-2 and HER-3 expression were determined in metastatic tissue of diagnosti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The ASHA Leader
سال: 2020
ISSN: 1085-9586
DOI: 10.1044/leader.fplp.25042020.72